Overview
The aim of this study is to discover the immune and oncogenomic features that distinguish patients who respond to teclistamab from patients who are primarily resistant. Moreover, phenotypic and genotypic characteristics that occur with secondary resistance to teclistamab will be analyzed.
Eligibility
Inclusion Criteria:
- With multiple myeloma
- Who receive Teclistamab
- Consent form signed
Exclusion Criteria:
- Patient under legal protection